NOTES PAYABLE - Credit Facility (Details) - USD ($) $ / shares in Units, $ in Millions					1 Months Ended	12 Months Ended		13 Months Ended
	Jul. 01, 2015	Mar. 24, 2015	Jan. 12, 2015	Nov. 13, 2014	Jun. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Nov. 30, 2014
Line of Credit Facility [Line Items]
Grant date fair value of the Warrants recorded as a derivative liability (in dollars per share)						$ 2.5	$ 2.5
Credit Facility
Line of Credit Facility [Line Items]
Number of common stock called by warrants (in shares)			125,000
Cash payment to Lenders			$ 0.6
Value Of Warrant Or Right Number Of Securities Called By Warrants Or Rights			1.1
Issuance of common stock in connection with public offering, net of fees		$ 140.0
Payment due to Asklepion upon closing			27.0
Prepayment premium	$ 2.3
Additional charge of prepayment premium	$ 4.2
Credit Agreement
Line of Credit Facility [Line Items]
Number of common stock called by warrants (in shares)							337,500
Exercise price (in dollars per share)							$ 12.76
Credit Agreement | Convertible Notes Payable
Line of Credit Facility [Line Items]
Credit agreement amount					$ 45.0
LIBOR Rate | Credit Agreement | Convertible Notes Payable
Line of Credit Facility [Line Items]
Debt instrument basis points added percentage					10.00%
Base Rate | Credit Agreement | Convertible Notes Payable
Line of Credit Facility [Line Items]
Debt instrument basis points added percentage					9.00%
Amendment No. 3 | Definitive Agreement | Athyrium Capital Management, LLC and Perceptive Credit Opportunities Fund, LP
Line of Credit Facility [Line Items]
Credit agreement amount			$ 30.0
Number of common stock called by warrants (in shares)			125,000
Clinuvel Pharmaceuticals Limited | Amendment No. 2 | Credit Agreement | Note Payable With Detachable Warrants
Line of Credit Facility [Line Items]
Number of common stock called by warrants (in shares)				300,000				300,000
Exercise price (in dollars per share)				$ 9.96
Value of common stock exercisable by warrants				$ 2.2				$ 2.2